Patents Assigned to ID Biomedical Corporation
-
Patent number: 7776335Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: August 17, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7749499Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: July 6, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7740870Abstract: The present invention relates to antigens, more particularly antigens of Group B Streptococcus (GBS) (S. agalactiae) which may be useful to prevent, diagnose and/or treat streptococcal infections.Type: GrantFiled: June 9, 2008Date of Patent: June 22, 2010Assignee: ID Biomedical CorporationInventors: Denis Martin, Stéphane Rioux, Bernard R. Brodeur, Josée Hamel, Martine Boyer
-
Publication number: 20100119507Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: ApplicationFiled: September 28, 2009Publication date: May 13, 2010Applicant: ID BIOMEDICAL CORPORATIONInventors: Denis Martin, Bernard Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
-
Publication number: 20100093035Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: ApplicationFiled: December 9, 2009Publication date: April 15, 2010Applicant: ID BIOMEDICAL CORPORATIONInventors: Josee Hamel, Bernard R. Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
-
Publication number: 20090324639Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: ApplicationFiled: April 28, 2008Publication date: December 31, 2009Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Publication number: 20090318337Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: ApplicationFiled: October 22, 2004Publication date: December 24, 2009Applicant: ID Biomedical Corporation of QuebecInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Patent number: 7635482Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: August 29, 2006Date of Patent: December 22, 2009Assignee: ID Biomedical CorporationInventors: Josee Hamel, Bernard R. Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
-
Publication number: 20090252762Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.Type: ApplicationFiled: March 30, 2009Publication date: October 8, 2009Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
-
Patent number: 7595057Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: GrantFiled: December 21, 2001Date of Patent: September 29, 2009Assignee: ID Biomedical CorporationInventors: Denis Martin, Bernard Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
-
Publication number: 20090186820Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.Type: ApplicationFiled: January 12, 2009Publication date: July 23, 2009Applicant: ID BIOMEDICAL CORPORATIONInventors: Denis Martin, Stephane Rioux, Bernard R. Brodeur, Josee Hamel, Patrick Rheault
-
Publication number: 20090175903Abstract: Compositions and methods for making and using therapeutic formulations of measles virus antigens with a Proteosome-based adjuvant are provided. The measles virus antigens may be derived from a variety of sources, such as from recombinant production or from a split antigen preparation. The measles vaccine formulations may be used, for example, in methods for treating or preventing a measles virus infection and eliciting a protective immune response.Type: ApplicationFiled: July 29, 2008Publication date: July 9, 2009Applicants: ID BIOMEDICAL CORPORATION OF QUEBEC, MCGILL UNIVERSITYInventors: Brian J. Ward, David S. Burt, Sophie Chabot
-
Patent number: 7528245Abstract: Nucleic acid expression control sequence cassettes and vectors containing the same are provided for use in making abundant quantities of recombinant polypeptides of interest. The modified transcriptional control sequences, which include a T5 promoter sequence, are highly stable and can be used in a variety of vectors, such as plasmids.Type: GrantFiled: August 22, 2005Date of Patent: May 5, 2009Assignee: ID Biomedical Corporation of WashingtonInventor: Mary ChaoHong Hu
-
Patent number: 7524509Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.Type: GrantFiled: March 11, 2002Date of Patent: April 28, 2009Assignee: ID Biomedical Corporation of QuebecInventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
-
Publication number: 20090074807Abstract: The present invention relates to polypeptides of Moraxella (Branhamella) catarrhalis which may be useful for prophylaxis, diagnostic and/or therapy purposes.Type: ApplicationFiled: July 15, 2008Publication date: March 19, 2009Applicant: ID BIOMEDICAL CORPORATIONInventors: Denis Martin, Josee Hamel, Bernard R. Brodeur, Stephane Rioux, Julie Couture
-
Publication number: 20090042794Abstract: The present invention relates to antigens, more particularly antigens of Group B Streptococcus (GBS) (S. agalactiae) which may be useful to prevent, diagnose and/or treat streptococcal infections.Type: ApplicationFiled: June 9, 2008Publication date: February 12, 2009Applicant: ID BIOMEDICAL CORPORATIONInventors: Denis Martin, Stephane Rioux, Bernard R. Brodeur, Josee Hamel, Martine Boyer
-
Patent number: 7482012Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.Type: GrantFiled: February 21, 2002Date of Patent: January 27, 2009Assignee: ID Biomedical CorporationInventors: Denis Martin, Stephane Rioux, Bernard R. Brodeur, Josee Hamel, Patrick Rheault
-
Patent number: 7459165Abstract: The present invention relates to polypeptides of Pseudomonas aeruginosa which may be used to prevent, diagnose and/or treat Pseudomonas aeruginosa infection.Type: GrantFiled: November 13, 2002Date of Patent: December 2, 2008Assignee: ID Biomedical CorporationInventors: Nathalie Charland, Josee Hamel, Bernard Brodeur, Denis Martin, Isabelle Charlebois, Diane Bussiere
-
Publication number: 20080254067Abstract: The present invention relates to a commercial-scale process for the production of influenza virus or antigens for prophylactic, diagnostic, immunotherapeutic or therapeutic purposes. Particularly, the invention provides a Madin-Darby Canine Kidney (MDCK)-derived, cell line and a cell culture-based process for the production of an influenza vaccine and more particularly, a human vaccine comprising influenza types A and B.Type: ApplicationFiled: May 20, 2005Publication date: October 16, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Pierre Trepanier, Robert Dugre, Tom Hassell
-
Publication number: 20080227706Abstract: Group B Streptococcus polypeptides and polynucleotides encoding them are disclosed. Said polypeptides may be useful for the prophylaxis, diagnostic and/or therapy of streptococcal infection in mammals. Also disclosed are recombinant methods of producing the polypeptide antigens as well as diagnostic assays for detecting streptococcal infections, particularly GBS.Type: ApplicationFiled: January 22, 2008Publication date: September 18, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Denis Martin, Stephane Rioux, Martine Boyer, Josee Hamel, Bernard R. Brodeur